17-AAG Kills Intracellular Leishmania amazonensis while Reducing Inflammatory Responses in Infected Macrophages

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Petersen, Antonio Luis de Oliveira Almeida ^a,b   Guedes, Carlos Eduardo Sampaio ^a   Versoza, Carolina Leite ^a   Lima, José Geraldo Bomfim ^a,b   de Freitas, Luiz Antônio Rodrigues ^a,b   Borges, Valéria Matos ^a   Veras, Patrícia Sampaio Tavares ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN; NITRIC OXIDE; SUPEROXIDE; TANESPIMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL VACUOLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG TARGETING; FEMALE; IN VITRO STUDY; LEISHMANIA; LEISHMANIASIS; MACROPHAGE; MALE; MICROSCOPY; NONHUMAN; PARASITE CLEARANCE; PARASITE LOAD; PARASITE VIABILITY; QUANTITATIVE STUDY; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; AUTOPHAGY; BENZOQUINONES; CELL SURVIVAL; CYTOKINES; FEMALE; INFLAMMATION; INFLAMMATION MEDIATORS; INTRACELLULAR SPACE; LACTAMS, MACROCYCLIC; LEISHMANIA MEXICANA; LEISHMANIASIS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; OXIDATION-REDUCTION; OXYGEN; PARASITE LOAD; PARASITES;

LEISHMANIA AMAZONENSIS;

EID: 84869040743     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049496     Document Type: Article

References (60)

1. Desjeux P, (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305-318.
2. Kedzierski L, Zhu Y, Handman E, (2006) Leishmania vaccines: progress and problems. Parasitology 133Suppl: S87-112.
3. Croft SL, Coombs GH, (2003) Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-508.
4. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BP, Nakamura CV, (2011) Recent advances in leishmaniasis treatment. Int J Infect Dis 15: e525-532.
5. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
6. Antoniou T, Gough KA, (2005) Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature. Pharmacotherapy 25: 899-903.
7. Assan R, Perronne C, Assan D, Chotard L, Mayaud C, et al. (1995) Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 18: 47-55.
8. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
9. Seifert K, (2011) Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open Med Chem J 5: 31-39.
10. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, et al. (1997) The amino-terminal domain of heat shock protein 90 (HSP90) that binds geldanamycin is an ATP/ADP switch domain that regulates Hsp90 conformation. J Biol Chem 272: 23843-23850.
11. Neckers L, (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8: S55-61.
12. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, et al. (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90: 65-75.
13. Gomez-Monterrey I, Sala M, Musella S, Campiglia P (2012) Heat Shock Protein 90 Inhibitors as Therapeutic Agents. Recent Pat Anticancer Drug Discov.
14. Whitesell L, Lindquist SL, (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772.
15. Folgueira C, Requena JM, (2007) A postgenomic view of the heat shock proteins in kinetoplastids. FEMS Microbiol Rev 31: 359-377.
16. Nathan DF, Vos MH, Lindquist S, (1997) In vivo functions of the Saccharomyces cerevisiae Hsp90 chaperone. Proc Natl Acad Sci U S A 94: 12949-12956.
17. Scheibel T, Buchner J, (1998) The Hsp90 complex-a super-chaperone machine as a novel drug target. Biochem Pharmacol 56: 675-682.
18. Wiesgigl M, Clos J, (2001) Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani. Mol Biol Cell 12: 3307-3316.
19. Banumathy G, Singh V, Pavithra SR, Tatu U, (2003) Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem 278: 18336-18345.
20. Kumar R, Musiyenko A, Barik S, (2005) Plasmodium falciparum calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin. Mol Biochem Parasitol 141: 29-37.
21. Pallavi R, Roy N, Nageshan RK, Talukdar P, Pavithra SR, et al. (2010) Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem 285: 37964-37975.
22. Ahn HJ, Kim S, Nam HW, (2003) Molecular cloning of the 82-kDa heat shock protein (HSP90) of Toxoplasma gondii associated with the entry into and growth in host cells. Biochem Biophys Res Commun 311: 654-659.
23. Brandau S, Dresel A, Clos J, (1995) High constitutive levels of heat-shock proteins in human-pathogenic parasites of the genus Leishmania. Biochem J 310 (Pt 1): 225-232.
24. Li Q, Zhou Y, Yao C, Ma X, Wang L, et al. (2009) Apoptosis caused by Hsp90 inhibitor geldanamycin in Leishmania donovani during promastigote-to-amastigote transformation stage. Parasitol Res 105: 1539-1548.
25. Shonhai A, Maier AG, Przyborski JM, Blatch GL, (2011) Intracellular protozoan parasites of humans: the role of molecular chaperones in development and pathogenesis. Protein Pept Lett 18: 143-157.
26. Schulte TW, Neckers LM, (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42: 273-279.
27. Isaacs JS, Xu W, Neckers L, (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3: 213-217.
28. Gomes IN, Calabrich AF, Tavares Rda S, Wietzerbin J, de Freitas LA, et al. (2003) Differential properties of CBA/J mononuclear phagocytes recovered from an inflammatory site and probed with two different species of Leishmania. Microbes Infect 5: 251-260.
29. Veras PS, Welby-Borges M, de Santana CD, Nihei J, Cardillo F, et al. (2006) Leishmania amazonensis: participation of regulatory T and B cells in the in vitro priming (PIV) of CBA/J spleen cells susceptible response. Exp Parasitol 113: 201-205.
30. Hothersall JS, Gordge M, Noronha-Dutra AA, (1998) Inhibition of NADPH supply by 6-aminonicotinamide: effect on glutathione, nitric oxide and superoxide in J774 cells. FEBS Lett 434: 97-100.
31. Ding AH, Nathan CF, Stuehr DJ, (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412.
32. de Sa MS, Costa JF, Krettli AU, Zalis MG, Maia GL, et al. (2009) Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice. Parasitol Res 105: 275-279.
33. Courret N, Frehel C, Prina E, Lang T, Antoine JC, (2001) Kinetics of the intracellular differentiation of Leishmania amazonensis and internalization of host MHC molecules by the intermediate parasite stages. Parasitology 122: 263-279.
34. Roy N, Nageshan RK, Ranade S, Tatu U, (2012) Heat shock protein 90 from neglected protozoan parasites. Biochim Biophys Acta 1823: 707-711.
35. Kumar R, Musiyenko A, Barik S, (2003) The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin. Malar J 2: 30.
36. Neckers L, Tatu U, (2008) Molecular chaperones in pathogen virulence: emerging new targets for therapy. Cell Host Microbe 4: 519-527.
37. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, et al. (2003) 17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol Cancer Ther 2: 123-129.
38. Antoine JC, Prina E, Jouanne C, Bongrand P, (1990) Parasitophorous vacuoles of Leishmania amazonensis-infected macrophages maintain an acidic pH. Infect Immun 58: 779-787.
39. Prina E, Antoine JC, Wiederanders B, Kirschke H, (1990) Localization and activity of various lysosomal proteases in Leishmania amazonensis-infected macrophages. Infect Immun 58: 1730-1737.
40. Liese J, Schleicher U, Bogdan C, (2008) The innate immune response against Leishmania parasites. Immunobiology 213: 377-387.
41. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
42. Chen F, Pandey D, Chadli A, Catravas JD, Chen T, et al. (2011) Hsp90 regulates NADPH oxidase activity and is necessary for superoxide but not hydrogen peroxide production. Antioxid Redox Signal 14: 2107-2119.
43. Kone BC, Kuncewicz T, Zhang W, Yu ZY, (2003) Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol 285: F178-190.
44. Luo S, Wang T, Qin H, Lei H, Xia Y, (2011) Obligatory role of heat shock protein 90 in iNOS induction. Am J Physiol Cell Physiol 301: C227-233.
45. Yoshida M, Xia Y, (2003) Heat shock protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase. J Biol Chem 278: 36953-36958.
46. Chatterjee A, Dimitropoulou C, Drakopanayiotakis F, Antonova G, Snead C, et al. (2007) Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am J Respir Crit Care Med 176: 667-675.
47. Poulaki V, Iliaki E, Mitsiades N, Mitsiades CS, Paulus YN, et al. (2007) Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J 21: 2113-2123.
48. Wax S, Piecyk M, Maritim B, Anderson P, (2003) Geldanamycin inhibits the production of inflammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts. Arthritis Rheum 48: 541-550.
49. Moll H (1997) The role of chemokines and accessory cells in the immunoregulation of cutaneous leishmaniasis. Behring Inst Mitt: 73-78.
50. Titus RG, Sherry B, Cerami A, (1989) Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 170: 2097-2104.
51. Romagnani S, (1991) Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 21: 152-158.
52. Besteiro S, Williams RA, Morrison LS, Coombs GH, Mottram JC, (2006) Endosome sorting and autophagy are essential for differentiation and virulence of Leishmania major. J Biol Chem 281: 11384-11396.
53. Williams RA, Tetley L, Mottram JC, Coombs GH, (2006) Cysteine peptidases CPA and CPB are vital for autophagy and differentiation in Leishmania mexicana. Mol Microbiol 61: 655-674.
54. Shintani T, Klionsky DJ, (2004) Autophagy in health and disease: a double-edged sword. Science 306: 990-995.
55. Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, et al. (2001) Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65: 87-89.
56. Miller RA, Britigan BE, (1997) Role of oxidants in microbial pathophysiology. Clin Microbiol Rev 10: 1-18.
57. Oliveira F, Bafica A, Rosato AB, Favali CB, Costa JM, et al. (2011) Lesion size correlates with Leishmania antigen-stimulated TNF-α levels in human cutaneous leishmaniasis. Am J Trop Med Hyg 85: 70-73.
58. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, et al. (2009) Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 9: 1479-1492.
59. Neckers L, Workman P, (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64-76.
60. Usmani SZ, Bona R, Li Z, (2009) 17 AAG for HSP90 inhibition in cancer-from bench to bedside. Curr Mol Med 9: 654-664.